The US Food and Drug Administration (FDA) has granted approval for Abbott’s Eterna spinal cord stimulation (SCS) system for the treatment of chronic pain.

The Eterna SCS system is said to be the smallest implantable, rechargeable system which is currently available on the market for this indication.

It uses the company’s low-dose BurstDR stimulation, the SCS waveform technology that mimics the natural firing patterns which are found in the brain to provide superior pain relief.

The company stated that the SCS technology has shown 23% more pain reduction compared to traditional waveform technology approaches.

It also noted that the Eterna SCS system has been developed based on extensive studies conducted with patients, physicians, and caregivers for understanding the unmet requirements of chronic pain patients.

The studies found that people preferred a smaller implant, with a reduced need to charge the device daily or weekly.

Eterna SCS system can be wirelessly charged less than five times a year under normal use, which is said to be the lowest recharge burden compared to other SCS systems.

Abbott neuromodulation vice-president Pedro Malha said: “At Abbott, we deliver products and solutions with the goal of simplifying healthcare, improving clinical outcomes, and providing people suffering from chronic pain with the best experience possible. As we progress on this commitment, Eterna is the next major leap forward.

“Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimised recharging experience – all key features when selecting the best overall system.”

The company said that the new neuromodulation device uses its TotalScan MRI technology that allows for full-body MRI scans for chronic pain patients who need improved diagnostics and healthcare.

Additionally, its patient-focused mobile app displays real-time battery life and charging status updates of the Eterna SCS system on a personal or Abbott-provided dedicated Apple device.